The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis-what happens next? A personal viewpoint

Diabetic Medicine

Volumn 30, Issue 12, 2013, Pages 1510-1511

  Ryder, R E J ^a   Sen Gupta, P ^a,b   Thong, K Y ^a  

^a CITY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; LIRAGLUTIDE; ORAL CONTRACEPTIVE AGENT; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ALCOHOL CONSUMPTION; ASSOCIATION OF BRITISH CLINICAL DIABETOLOGIST; DEEP VEIN THROMBOSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GALLSTONE; GLYCEMIC CONTROL; HAZARD RATIO; HEALTH CARE ORGANIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; LETTER; MEDICAL AUDIT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RHABDOMYOLYSIS; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INCRETINS; MALE; PANCREATITIS;

EID: 84887605043     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12336     Document Type: Letter

References (10)

1. Robson J. Incretins and pancreatitis-what happens next? A personal viewpoint. Diabet Med 2013; 30: 1156-1159.
2. Ryder REJ, Thong KY, on behalf of the ABCD nationwide exenatide audit contributors. Incidence of acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. 2013. Available at http://www.diabetologistsabcd.org.uk/GLP1_Audits/pancreatitis_incidence_exenatide_audit.pdf Last accessed 3 October 2013.
3. Ryder REJ, Thong KY, Blann AD, Phillips SM, Barwell ND, Kelly CJC et al. on behalf of the ABCD nationwide liraglutide audit contributors. Liraglutide pancreatitis: the ABCD nationwide liraglutide audit. Br J Diabetes Vasc Dis 2013; doi: 10.1177/1474651413502685 [Epub ahead of print].
4. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE et al. Patients with Type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diab Obes Metab 2010; 12: 766-771.
5. Garg R, Chen W, Pendergrass M. Acute pancreatitis in Type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
6. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with Type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838.
7. Gonzalez-Perez A, Schlienger RG, Rodríguez LA. Acute pancreatitis in association with Type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010; 33: 2580-2585.
8. Banks PA. Epidemiology, natural history, and predictors of disease outcome in acute and chronic pancreatitis. Gastrointest Endosc 2002; 56: S226-230.
9. Venneman NG, van Brummelen SE, van Berge-Henegouwen GP, van Erpecum KJ. Microlithiasis: an important cause of 'idiopathic' acute pancreatitis? Ann Hepatol 2003; 2: 30-35.
10. Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M et al. Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobil Pancreat Surg 2006; 13: 10-24.